ANI paid US$25 million in cash and will give a percentage of future gross profits from sales of the generics. The generics in question include 19 solid-oral dosage products and three oral suspension products.

ANI intends to initially focus on the technology transfer for four products that qualify as CBE30 filings (Changes Being Effected: a filing with the FDA to gain approval of a moderate change) into ANI’s two manufacturing facilities in Baudette, Minnesota, USA. These four products have a combined market value of US$210 million for the last 12 months. The total market value for all 22 products is US$650 million for the last twelve months.

ANI also acquired 31 generics from Teva back in December 2013 and the company has a generic testosterone gel partnership with Teva [1]. This latest deal expands ANI’s product pipeline to 68 products with a total market value of US$3.9 billion, according to IMS Health.

Reference
1. GaBI Online - Generics and Biosimilars Initiative. ANI Pharmaceuticals acquires 31 generics from Teva [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Aug 14]. Available from: www.gabionline.net/Generics/News/ANI-Pharmaceuticals-acquires-31-generics-from-Teva

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.